201 related articles for article (PubMed ID: 33722931)
21. Genetic podocyte lineage reveals progressive podocytopenia with parietal cell hyperplasia in a murine model of cellular/collapsing focal segmental glomerulosclerosis.
Suzuki T; Matsusaka T; Nakayama M; Asano T; Watanabe T; Ichikawa I; Nagata M
Am J Pathol; 2009 May; 174(5):1675-82. PubMed ID: 19359523
[TBL] [Abstract][Full Text] [Related]
22. Regulation of TRPC6 ion channels in podocytes - Implications for focal segmental glomerulosclerosis and acquired forms of proteinuric diseases.
Szabó T; Ambrus L; Zákány N; Balla G; Bíró T
Acta Physiol Hung; 2015 Sep; 102(3):241-51. PubMed ID: 26551740
[TBL] [Abstract][Full Text] [Related]
23. Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?
Novelli R; Gagliardini E; Ruggiero B; Benigni A; Remuzzi G
Am J Physiol Renal Physiol; 2016 Mar; 310(5):F335-41. PubMed ID: 26697986
[TBL] [Abstract][Full Text] [Related]
24. Baicalin alleviates adriamycin-induced focal segmental glomerulosclerosis and proteinuria by inhibiting the Notch1-Snail axis mediated podocyte EMT.
Dou Y; Shang Y; Shen Y; Qu J; Liu C; Cao J
Life Sci; 2020 Sep; 257():118010. PubMed ID: 32598932
[TBL] [Abstract][Full Text] [Related]
25. In situ evaluation of podocytes in patients with focal segmental glomerulosclerosis and minimal change disease.
da Silva CA; Monteiro MLGDR; Araújo LS; Urzedo MG; Rocha LB; Dos Reis MA; Machado JR
PLoS One; 2020; 15(11):e0241745. PubMed ID: 33147279
[TBL] [Abstract][Full Text] [Related]
26. Pathobiology of focal segmental glomerulosclerosis: new developments.
D'Agati VD
Curr Opin Nephrol Hypertens; 2012 May; 21(3):243-50. PubMed ID: 22357339
[TBL] [Abstract][Full Text] [Related]
27. Activation of necroptosis pathway in podocyte contributes to the pathogenesis of focal segmental glomerular sclerosis.
Hu H; Li M; Chen B; Guo C; Yang N
Clin Exp Nephrol; 2022 Nov; 26(11):1055-1066. PubMed ID: 35925422
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of CD44-positive glomerular parietal epithelial cells reflects podocyte injury in adriamycin nephropathy.
Okamoto T; Sasaki S; Yamazaki T; Sato Y; Ito H; Ariga T
Nephron Exp Nephrol; 2013; 124(3-4):11-8. PubMed ID: 24401840
[TBL] [Abstract][Full Text] [Related]
29. Role of fibroblast specific protein 1 expression in the progression of adriamycin-induced glomerulosclerosis.
Nakatani K; Asai O; Konishi N; Iwano M
Biochem Biophys Res Commun; 2021 Aug; 567():148-153. PubMed ID: 34153685
[TBL] [Abstract][Full Text] [Related]
30. CD147/Basigin Deficiency Prevents the Development of Podocyte Injury through FAK Signaling.
Yoshioka T; Kosugi T; Masuda T; Watanabe T; Ryuge A; Nagaya H; Maeda K; Sato Y; Katsuno T; Kato N; Ishimoto T; Yuzawa Y; Maruyama S; Kadomatsu K
Am J Pathol; 2019 Jul; 189(7):1338-1350. PubMed ID: 31014956
[TBL] [Abstract][Full Text] [Related]
31. Focal segmental glomerulosclerosis; why does it occur segmentally?
Nagata M; Kobayashi N; Hara S
Pflugers Arch; 2017 Aug; 469(7-8):983-988. PubMed ID: 28664408
[TBL] [Abstract][Full Text] [Related]
32. Role of C/EBP-α in Adriamycin-induced podocyte injury.
Zhong F; Wang W; Lee K; He JC; Chen N
Sci Rep; 2016 Sep; 6():33520. PubMed ID: 27644413
[TBL] [Abstract][Full Text] [Related]
33. Transcription factor MafB in podocytes protects against the development of focal segmental glomerulosclerosis.
Usui T; Morito N; Shawki HH; Sato Y; Tsukaguchi H; Hamada M; Jeon H; Yadav MK; Kuno A; Tsunakawa Y; Okada R; Ojima T; Kanai M; Asano K; Imamura Y; Koshida R; Yoh K; Usui J; Yokoi H; Kasahara M; Yoshimura A; Muratani M; Kudo T; Oishi H; Yamagata K; Takahashi S
Kidney Int; 2020 Aug; 98(2):391-403. PubMed ID: 32622525
[TBL] [Abstract][Full Text] [Related]
34. Podocytes exhibit a specialized protein quality control employing derlin-2 in kidney disease.
Ren G; Tardi NJ; Matsuda F; Koh KH; Ruiz P; Wei C; Altintas MM; Ploegh H; Reiser J
Am J Physiol Renal Physiol; 2018 Mar; 314(3):F471-F482. PubMed ID: 29167172
[TBL] [Abstract][Full Text] [Related]
35. Activation of NFAT signaling in podocytes causes glomerulosclerosis.
Wang Y; Jarad G; Tripathi P; Pan M; Cunningham J; Martin DR; Liapis H; Miner JH; Chen F
J Am Soc Nephrol; 2010 Oct; 21(10):1657-66. PubMed ID: 20651158
[TBL] [Abstract][Full Text] [Related]
36. SRGAP1 Controls Small Rho GTPases To Regulate Podocyte Foot Process Maintenance.
Rogg M; Maier JI; Dotzauer R; Artelt N; Kretz O; Helmstädter M; Abed A; Sammarco A; Sigle A; Sellung D; Dinse P; Reiche K; Yasuda-Yamahara M; Biniossek ML; Walz G; Werner M; Endlich N; Schilling O; Huber TB; Schell C
J Am Soc Nephrol; 2021 Mar; 32(3):563-579. PubMed ID: 33514561
[TBL] [Abstract][Full Text] [Related]
37. Intrinsic tumor necrosis factor-α pathway is activated in a subset of patients with focal segmental glomerulosclerosis.
Chung CF; Kitzler T; Kachurina N; Pessina K; Babayeva S; Bitzan M; Kaskel F; Colmegna I; Alachkar N; Goodyer P; Cybulsky AV; Torban E
PLoS One; 2019; 14(5):e0216426. PubMed ID: 31095586
[TBL] [Abstract][Full Text] [Related]
38. The Hippo pathway regulator KIBRA promotes podocyte injury by inhibiting YAP signaling and disrupting actin cytoskeletal dynamics.
Meliambro K; Wong JS; Ray J; Calizo RC; Towne S; Cole B; El Salem F; Gordon RE; Kaufman L; He JC; Azeloglu EU; Campbell KN
J Biol Chem; 2017 Dec; 292(51):21137-21148. PubMed ID: 28982981
[TBL] [Abstract][Full Text] [Related]
39. Podocyte injury-driven lipid peroxidation accelerates the infiltration of glomerular foam cells in focal segmental glomerulosclerosis.
Hara S; Kobayashi N; Sakamoto K; Ueno T; Manabe S; Takashima Y; Hamada J; Pastan I; Fukamizu A; Matsusaka T; Nagata M
Am J Pathol; 2015 Aug; 185(8):2118-31. PubMed ID: 26072030
[TBL] [Abstract][Full Text] [Related]
40. Partial podocyte replenishment in experimental FSGS derives from nonpodocyte sources.
Kaverina NV; Eng DG; Schneider RR; Pippin JW; Shankland SJ
Am J Physiol Renal Physiol; 2016 Jun; 310(11):F1397-413. PubMed ID: 27076646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
